Navigation Links
Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
Date:11/28/2012

JUPITER, FL, November 28, 2012 Scientists from the Florida campus of The Scripps Research Institute (TSRI) have uncovered a group of what have been considered relatively minor regulators in the body that band together to suppress the spread of cancer from its primary site.

The discovery offers a fresh batch of possible therapeutic targets as well as new diagnostic tools with the potential to predict and inhibit the spread of cancer (metastasis) in patients suffering from the disease.

The research, published recently in The Journal of Biological Chemistry, was conducted by TSRI Professor Donald G. Phinney, a nationally recognized authority in the study of adult bone marrow-derived stem cells, and a postdoctoral fellow in his laboratory, Christopher L. Haga.

In the new study, the scientists found that a cluster of seven microRNAs (miRNA) function cooperatively to repress a process known as epithelial-to-mesenchymal transition (EMT). While EMT is part of the normal biology of cell development in some parts of the body, the process has recently been implicated in two dangerous aspects of tumor growthtumor metastasis and the growth of drug-resistant cancer stem cells.

MicroRNAs are tiny fragments of RNA found in all mammalian cells. They bind to messenger RNAs, a process that generally results in gene silencing. This cluster of miRNAs, located in a genetic region known as DLK1-DIO3, suppresses a specific signaling network in human cancers that primarily affect glands such as breast cancer.

"These results establish the DLKI-DIO3 miRNA cluster as a critical checkpoint regulating tumor growth and metastasis," said Phinney. "Our data shows that when this cluster is silenced, it accelerates tumorogenesis and proliferation by inducing EMT."

Silencing the DLK1-DIO3 genetic region is an early event for tumors, Phinney said, pointing out that micro-metastasis can be detected even in the early stages of breast cancer.

One of the seven miRNAs highlighted in the new studyMiR-544appears to be potent in its powers of inhibition, repressing cancer cell proliferation by inducing Ataxia telangiectasia mutated (ATM), a protein involved in stopping the cell cycle once DNA damage is detected.

"What's interesting is that MiR-544 blocks cell growth in every tumor cell line we've put it into, so we're looking at it as a potential therapeutic target," Phinney said.

Phinney noted that dozens of miRNAs exist in the same genetic region. "It's possible there are other clusters that work together to affect tumor growth and metastasis," he said.


'/>"/>

Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute
Source:Eurekalert  

Related medicine news :

1. Scripps Research Institute study points to potential new therapies for cancer and other diseases
2. 2 Scripps Research Institute scientists honored by American Chemical Society
3. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
4. Scripps Research Institute receives $20 million to shed light on HIV drug resistance
5. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
6. Scripps Research scientists devise powerful new method for finding therapeutic antibodies
7. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
8. Scripps Florida scientists awarded nearly $1.5 million to develop new approaches to treat cancer
9. Scripps Research scientists show how memory B cells stay in class to fight different infections
10. Cleveland Clinic Florida receives approval for transplant programs at Weston Facilities
11. Chinese Drywall Complaint Center Now Demands Leadership From Obama & EPA, For Homeowners In Florida And In The US Southeast Stuck In Toxic Chinese Drywall Hell-Forward?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: